The natural history of resected pancreatic cancer without adjuvant chemotherapy

Jonathan M. Hernandez, Connor A. Morton, Sam Al-Saadi, Desireé Villadolid, Jennifer Cooper, Carl Bowers, Alexander S. Rosemurgy

Research output: Contribution to journalArticle

31 Citations (Scopus)

Abstract

Diagnostic imaging, surgical care, and perioperative morbidity and mortality have significantly improved for patients undergoing resections for pancreatic adenocarcinoma. This study was undertaken to define the natural history and patterns of recurrence of resected pancreatic cancer without neoadjuvant or adjuvant therapies using current standards of care. Sixty-one patients underwent pancreatectomy without neoadjuvant or adjuvant therapy. Tumors were staged according to the American Joint Committee on Cancer (AJCC) classification system. CTscans were obtained every 3 months and recurrence categorized as: liver only, local, distant, multiple sites, or clinical. Median survival after pancreatectomy was 12 months. Cancer recurred in 51 (84%) patients. The radiographic site of initial recurrence did not generally impact survival; patients initially recurring at multiple sites had significantly abbreviated median survival of 5.6 months. AJCC stage was found to correlate with disease-free and overall survival, although tumor size alone did not. The presence of lymphatic metastasis correlated with disease-free but not overall survival. Overall survival after pancreaticoduodenectomy remains poor in the absence of neoadjuvant or adjuvant therapy. AJCC stage is the best predictor of disease-free and overall survival; tumor size, lymph node status, and site of recurrence alone do not impact survival in a meaningful way.

Original languageEnglish (US)
Pages (from-to)480-485
Number of pages6
JournalAmerican Surgeon
Volume76
Issue number5
StatePublished - May 1 2010

Fingerprint

Adjuvant Chemotherapy
Natural History
Pancreatic Neoplasms
Survival
Neoplasms
Recurrence
Pancreatectomy
Disease-Free Survival
Lymphatic Metastasis
Perioperative Care
Pancreaticoduodenectomy
Diagnostic Imaging
Standard of Care
Adenocarcinoma
Therapeutics
Lymph Nodes
Morbidity
Mortality
Liver

All Science Journal Classification (ASJC) codes

  • Surgery

Cite this

Hernandez, J. M., Morton, C. A., Al-Saadi, S., Villadolid, D., Cooper, J., Bowers, C., & Rosemurgy, A. S. (2010). The natural history of resected pancreatic cancer without adjuvant chemotherapy. American Surgeon, 76(5), 480-485.
Hernandez, Jonathan M. ; Morton, Connor A. ; Al-Saadi, Sam ; Villadolid, Desireé ; Cooper, Jennifer ; Bowers, Carl ; Rosemurgy, Alexander S. / The natural history of resected pancreatic cancer without adjuvant chemotherapy. In: American Surgeon. 2010 ; Vol. 76, No. 5. pp. 480-485.
@article{6567338d2d884bdcaac6940d3201c3dc,
title = "The natural history of resected pancreatic cancer without adjuvant chemotherapy",
abstract = "Diagnostic imaging, surgical care, and perioperative morbidity and mortality have significantly improved for patients undergoing resections for pancreatic adenocarcinoma. This study was undertaken to define the natural history and patterns of recurrence of resected pancreatic cancer without neoadjuvant or adjuvant therapies using current standards of care. Sixty-one patients underwent pancreatectomy without neoadjuvant or adjuvant therapy. Tumors were staged according to the American Joint Committee on Cancer (AJCC) classification system. CTscans were obtained every 3 months and recurrence categorized as: liver only, local, distant, multiple sites, or clinical. Median survival after pancreatectomy was 12 months. Cancer recurred in 51 (84{\%}) patients. The radiographic site of initial recurrence did not generally impact survival; patients initially recurring at multiple sites had significantly abbreviated median survival of 5.6 months. AJCC stage was found to correlate with disease-free and overall survival, although tumor size alone did not. The presence of lymphatic metastasis correlated with disease-free but not overall survival. Overall survival after pancreaticoduodenectomy remains poor in the absence of neoadjuvant or adjuvant therapy. AJCC stage is the best predictor of disease-free and overall survival; tumor size, lymph node status, and site of recurrence alone do not impact survival in a meaningful way.",
author = "Hernandez, {Jonathan M.} and Morton, {Connor A.} and Sam Al-Saadi and Desire{\'e} Villadolid and Jennifer Cooper and Carl Bowers and Rosemurgy, {Alexander S.}",
year = "2010",
month = "5",
day = "1",
language = "English (US)",
volume = "76",
pages = "480--485",
journal = "American Surgeon",
issn = "0003-1348",
publisher = "Southeastern Surgical Congress",
number = "5",

}

Hernandez, JM, Morton, CA, Al-Saadi, S, Villadolid, D, Cooper, J, Bowers, C & Rosemurgy, AS 2010, 'The natural history of resected pancreatic cancer without adjuvant chemotherapy', American Surgeon, vol. 76, no. 5, pp. 480-485.

The natural history of resected pancreatic cancer without adjuvant chemotherapy. / Hernandez, Jonathan M.; Morton, Connor A.; Al-Saadi, Sam; Villadolid, Desireé; Cooper, Jennifer; Bowers, Carl; Rosemurgy, Alexander S.

In: American Surgeon, Vol. 76, No. 5, 01.05.2010, p. 480-485.

Research output: Contribution to journalArticle

TY - JOUR

T1 - The natural history of resected pancreatic cancer without adjuvant chemotherapy

AU - Hernandez, Jonathan M.

AU - Morton, Connor A.

AU - Al-Saadi, Sam

AU - Villadolid, Desireé

AU - Cooper, Jennifer

AU - Bowers, Carl

AU - Rosemurgy, Alexander S.

PY - 2010/5/1

Y1 - 2010/5/1

N2 - Diagnostic imaging, surgical care, and perioperative morbidity and mortality have significantly improved for patients undergoing resections for pancreatic adenocarcinoma. This study was undertaken to define the natural history and patterns of recurrence of resected pancreatic cancer without neoadjuvant or adjuvant therapies using current standards of care. Sixty-one patients underwent pancreatectomy without neoadjuvant or adjuvant therapy. Tumors were staged according to the American Joint Committee on Cancer (AJCC) classification system. CTscans were obtained every 3 months and recurrence categorized as: liver only, local, distant, multiple sites, or clinical. Median survival after pancreatectomy was 12 months. Cancer recurred in 51 (84%) patients. The radiographic site of initial recurrence did not generally impact survival; patients initially recurring at multiple sites had significantly abbreviated median survival of 5.6 months. AJCC stage was found to correlate with disease-free and overall survival, although tumor size alone did not. The presence of lymphatic metastasis correlated with disease-free but not overall survival. Overall survival after pancreaticoduodenectomy remains poor in the absence of neoadjuvant or adjuvant therapy. AJCC stage is the best predictor of disease-free and overall survival; tumor size, lymph node status, and site of recurrence alone do not impact survival in a meaningful way.

AB - Diagnostic imaging, surgical care, and perioperative morbidity and mortality have significantly improved for patients undergoing resections for pancreatic adenocarcinoma. This study was undertaken to define the natural history and patterns of recurrence of resected pancreatic cancer without neoadjuvant or adjuvant therapies using current standards of care. Sixty-one patients underwent pancreatectomy without neoadjuvant or adjuvant therapy. Tumors were staged according to the American Joint Committee on Cancer (AJCC) classification system. CTscans were obtained every 3 months and recurrence categorized as: liver only, local, distant, multiple sites, or clinical. Median survival after pancreatectomy was 12 months. Cancer recurred in 51 (84%) patients. The radiographic site of initial recurrence did not generally impact survival; patients initially recurring at multiple sites had significantly abbreviated median survival of 5.6 months. AJCC stage was found to correlate with disease-free and overall survival, although tumor size alone did not. The presence of lymphatic metastasis correlated with disease-free but not overall survival. Overall survival after pancreaticoduodenectomy remains poor in the absence of neoadjuvant or adjuvant therapy. AJCC stage is the best predictor of disease-free and overall survival; tumor size, lymph node status, and site of recurrence alone do not impact survival in a meaningful way.

UR - http://www.scopus.com/inward/record.url?scp=77953533480&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77953533480&partnerID=8YFLogxK

M3 - Article

C2 - 20506876

AN - SCOPUS:77953533480

VL - 76

SP - 480

EP - 485

JO - American Surgeon

JF - American Surgeon

SN - 0003-1348

IS - 5

ER -

Hernandez JM, Morton CA, Al-Saadi S, Villadolid D, Cooper J, Bowers C et al. The natural history of resected pancreatic cancer without adjuvant chemotherapy. American Surgeon. 2010 May 1;76(5):480-485.